Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases

Pathology International

Volumn 53, Issue 7, 2003, Pages 422-428

  Yang, Ming ^a,b,c   Moriya, Takuya ^b   Oguma, Mitsue ^b,c   De La Cruz, Clarissa ^b   Endoh, Mareyuki ^b   Ishida, Takanori ^c   Hirakawa, Hisashi ^d   Orita, Yojiro ^e   Ohuchi, Noriaki ^c   Sasano, Hironobu ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Tohoku Kousai Hospital   (Japan)

^e Department of Surgery   (Japan)

Author keywords

Breast carcinoma; Ductal carcinoma in situ; Immunohistochemistry; Microinvasion; T1mic

Indexed keywords

EOSIN; ESTROGEN RECEPTOR; HEMATOXYLIN; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BASEMENT MEMBRANE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPHOCYTIC INFILTRATION; MAMMOGRAPHY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744228783     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01498.x     Document Type: Article

References (25)

1. Schuh ME, Nemoto T, Penetrante RB, Rosner D, Dao TL. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease. Arch Surg 1986; 121: 1303-7.
2. Rosner D, Lane WW, Penetrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer 1991; 67: 1498-503.
3. Silverstein MJ, Waisman JR, Gamagami P et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66: 102-8.
4. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer 1998; 82: 2382-90.
5. Solin LJ, Fowble BL, Yeh IT et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 1992; 23: 961-8.
6. Greene FL, Page DL, Fleming ID et al., eds. American Joint Committee on Cancer (AJCC) Staging Manual, 6th edition. Philadelphia: Lippincott-Raven, 2002; 223-40.
7. Sobin LH, Wittekind Ch, eds. International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 6th edition. New York, USA: Wiley-Liss, 2002.
8. Prasad MP, Osborne MP, Hoda SA. Observations on the histopathologic diagnosis of microinvasive carcinoma of the breast. In: Fechner RE, Rosen PP, eds. Anatomic Pathology, Vol. 3. Chicago, IL: ASCP Press, 1998; 209-32.
9. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 1994; 74: 2972-8.
10. Silverstein MJ, Poller DN, Waisman JR. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345: 1154-7.
11. Siziopikou KP, Prioleau JE, Harris JR, Schnitt SJ. bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 1996; 77: 499-506.
12. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast. Analysis of pathologic findings of 85 pure intraductal carcinomas. Int J Surg Pathol 1995; 3: 83-92.
13. Prasad ML, Osborne MP, Giri DD, Hoda SA. Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 2000; 24: 422-8.
14. Schnitt SJ. Microinvasive carcinoma of the breast: a diagnosis in search of a definition. Adv Anat Pathol 1998; 5: 367-72.
15. Silverstein MJ, Lagios MD. Ductal carcinoma in situ with microinvasion. In: Silverstein MJ, ed. Ductal Carcinoma in situ of the Breast, 2nd edition. Baltimore, MD: Lippincott Williams & Wilkins, 2002; 523-9.
16. Lagios MD, Westdahl PR, Margolin FR, Rose FR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982; 50: 1309-14.
17. Prasad ML, Giri D, Hoda S. Clinical pathologic features of microinvasion (<1mm) carcinoma of the breast [abstract]. Mod Pathol 1998; 11: 25A.
18. Silverstein MJ, Gierson ED, Colburn WJ, Rosser RJ, Waisman JR, Gamagami P. Axillary lymphadenectomy for intraductal carcinoma of the breast. Surg Gynecol Obstet 1991; 172: 211-14.
19. Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast: 10- to 20-year follow-up. Arch Surg 1992; 127: 468-72.
20. Patchefsky AS, Schwartz GF, Finkelstein SD et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989; 63: 731-41.
21. Rosen PP. Intraductal carcinoma. In: Rosen PP, ed. Rosen's Breast Pathology, 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 2001; 309.
22. Gupta SK, Douglas-Jones AG, Fenn N, Morgan JM, Mansel RE. The clinical behavior of breast carcinoma is probably determined in the preinvasive stage (ductal carcinoma in situ). Cancer 1997; 80: 1740-45.
23. Silver SA, Tavassoli FA. Microinvasive carcinoma of the breast: is axillary node dissection indicated? [abstract]. Mod Pathol 1997; 10: 25A.
24. Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg 1990; 125: 1298-302.
25. Penault-Liorca F, Le Bouedec G, Feillel V, Dauplat J, de Latour M. Microinvasive carcinoma of the breast: is axillary lymph node dissection indicated? [abstract]. Mod Pathol 1998; 11: 25A.